Tag: Array Biopharma

Finance

Investors Should Watch: Array BioPharma, Inc. (NASDAQ:ARRY), Comcast Corporation (NASDAQ:CMCSA), Tech Data Corp. (NASDAQ:TECD), Worthington Industries, Inc. (NYSE:WOR), LDR Holding Corporation (NASDAQ:LDRH)

On Dec 12, Oncothyreon Inc. announced that Array BioPharma, Inc. (NASDAQ:ARRY) has granted Oncothyreon an exclusive license to develop, manufacture and commercialize ONT-380 (ARRY-380), an orally active, reversible and selective small molecule HER2 inhibitor. The license agreement replaces the prior Development and Collaboration Agreement under which Oncothyreon and Array were jointly developing ONT-380. Array BioPharma, Inc. (NASDAQ:ARRY) belongs to Healthcare sector. Its weekly performance is … Continue reading Investors Should Watch: Array BioPharma, Inc. (NASDAQ:ARRY), Comcast Corporation (NASDAQ:CMCSA), Tech Data Corp. (NASDAQ:TECD), Worthington Industries, Inc. (NYSE:WOR), LDR Holding Corporation (NASDAQ:LDRH)

Chris Lewis
Finance

Why Need to Watch: Array BioPharma, Inc. (NASDAQ:ARRY), Hewlett-Packard Company (NYSE:HPQ), Polycom, Inc. (NASDAQ:PLCM), Endurance International Group (NASDAQ:EIGI), Diamond Offshore Drilling (NYSE:DO)

Array BioPharma, Inc. (NASDAQ:ARRY) announced that it has reached a definitive agreement with Novartis International Pharmaceutical Ltd. to regain full worldwide rights to binimetinib, a MEK inhibitor in three Phase 3 trials. This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline PLC on April 22, 2014, which are expected in the first half of 2015, and remain subject to regulatory … Continue reading Why Need to Watch: Array BioPharma, Inc. (NASDAQ:ARRY), Hewlett-Packard Company (NYSE:HPQ), Polycom, Inc. (NASDAQ:PLCM), Endurance International Group (NASDAQ:EIGI), Diamond Offshore Drilling (NYSE:DO)

Adam Keintzel